The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.
To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.
For additional information please review our Privacy Policy.
2008 ASCO–NCI–EORTC Annual Meeting on Molecular Markers in Cancer Program Agenda
Thursday, October 30, 2008 Exhibit Hall Open
3:00 PM – 7:00 PM
Welcome
2:00 PM – 2:10 PM
General Session I: Minimal Residual Disease and Circulating Tumor Cells
2:10 PM – 3:30 PM Chairs: Eric J. Small, MD – University of California San Francisco
Fred C. G. J. Sweep, PhD – Radboud University Nijmegen Medical Centre
Detection, Characterization, and Monitoring of Circulating Tumor Cells
Klaus Pantel, MD – University Medical Center Hamburg-Eppendorf
Isolation of Circulating Tumor Cells Using the Microfluidic Platform (the 'CTC-chip')
Lecia V. Sequist, MD, MPH – Massachusetts General Hospital
Foundation for NIH Biomarkers Consortium Initiative on Circulating Tumor Cells
Richard L. Schilsky, MD – University of Chicago
Break
3:30 PM – 4:00 PM
General Session I: Minimal Residual Disease and Circulating Tumor Cells (continued)
4:00 PM – 6:00 PM
Circulating Tumor Cell Detection and Phenotyping in Breast Cancer
Volkmar Müeller, MD, PhD – University Medical Center Hamburg-Eppendorf
Detection of Circulating Tumor Cells in Prostate Cancer
Johann S. de Bono, MD, FRCP, MSc, PhD – The Royal Marsden Hospital
BCR–ABL Assays for Recurrence and Resistance
Andreas Hochhaus, MD – Universitaetsklinikum Mannheim
Abstract Presentation
Panel Discussion and Question & Answer Session
Reception and General Poster Session A (Wine and Cheese Provided)
6:00 PM – 7:00 PM
Friday, October 31, 2008 Exhibit Hall Open
8:00 AM – 7:00 PM
Continental Breakfast Provided
8:00 AM – 9:00 AM
General Session II: Identifying Patients for EGFR Inhibitor Therapy: Markers of Response and Resistance
9:00 AM – 10:30 AM Co-Chairs: Bruce E. Johnson, MD – Dana-Farber Cancer Institute
Tracy G. Lively, PhD – National Cancer Institute
Overview: EGFR Pathway
Jose Baselga, MD – Hospital Vall D’Hebron
Molecular Markers of Response to EGFR Antibodies in Colon Cancer
Eric Van Cutsem, MD, PhD – University Hospital Gasthuisberg
Molecular Markers of Response to Cetuximab in Lung Cancer (FLEX Study)
Robert Pirker, MD – Medical University of Vienna
Molecular Markers of Response to EGFR Antibodies in Head and Neck Cancer
Jennifer R. Grandis, MD, FACS – University of Pittsburgh
Break
10:30 AM – 11:00 AM
General Session II: Identifying Patients for EGFR Inhibitor Therapy: Markers of Response and Resistance (continued)
11:00 AM – 12:30 PM
Molecular Markers of Resistance to EGFR Inhibitors
Pasi A. Janne, MD, PhD – Dana-Farber Cancer Institute
Imaging of EGFR
Wolfgang A. Weber, MD – University of Freiburg
Abstract Presentation
Panel Discussion and Question & Answer Session
General Poster Session B (Box Lunch Provided)
12:30 PM – 2:00 PM
General Session III: Challenges Importing Biomarkers into Clinical Trials
2:00 PM – 3:20 PM Co-Chairs: Vered Stearns, MD – Johns Hopkins Oncology Center
Susan G. Hilesenbeck, PhD – Lester and Sue Smith Breast Center at Baylor College of Medicine
Overview
Susan G. Hilsenbeck, PhD – Lester and Sue Smith Breast Center at Baylor College of Medicine
Vered Stearns, MD – Johns Hopkins Oncology Center
Challenges in Transporting Multi-Gene Classifiers to the Clinic
Lara Lusa, PhD – University of Ljubljana, Slovenia
Statistical Consideration for Incorporating Biomarkers into Trials
Gary M. Clark, PhD – Array BioPharma
Break
3:20 PM – 3:50 PM
General Session III: Challenges Importing Biomarkers into Clinical Trials (continued)
3:50 PM – 5:30 PM
Prospective Germline Pharmacogenetic Testing for Irinotecan and 5-Fluorouracil
Federico Innocenti, MD, PhD – University of Chicago
Panel Discussion: When is a Marker Ready for Trial?
Led by moderators and Christos Sotiriou, MD, PhD
General Poster Session C and Wine and Cheese Reception (hors d’oeuvres provided)
5:30 PM – 7:00 PM
Saturday, November 1, 2008 Continental Breakfast Provided
7:30 AM – 8:30 AM
General Session IV: Molecular Markers of Response and Resistance to Angiogenesis Inhibitors
8:30 AM – 10:15 AM Co-Chairs: Sigrid Stroobants, MD, PhD – U.Z. Gasthuisberg
Nadia Harbeck, MD, PhD – Inter Disciplinary Breast Center, Technische Universitaet Muenchen
Overview
Rakesh K. Jain, BSChE, MS, PhD – Harvard Medical School and Massachusetts General Hospital
VEGF and Predictors of Response to VEGFR2 Inhibitors
John Heymach, MD, PhD – M. D. Anderson Cancer Center
Molecular Markers of Response and Resistance to VEGFR Inhibitors in Brain Tumor
Tracy T. Batchelor, MD, MPH – Massachusetts General Hospital
Molecular Markers of Response and Resistance to VEGFR Inhibitors in Renal Cell Carcinoma
Brian I. Rini, MD – Cleveland Clinic Taussig Cancer Center
Break
10:15 AM – 10:45 AM
General Session IV: Molecular Markers of Response and Resistance to Angiogenesis Inhibitors (continued)
10:45 AM – 12:00 PM
Imaging and Angiogenesis Inhibitors
Daniel J. George, MD – Duke University Medical Center
